These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22086654)

  • 1. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.
    Lee JK; Park HS; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS; Kim WH; Bang YJ
    Cancer; 2012 Jul; 118(14):3579-86. PubMed ID: 22086654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
    Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC.
    Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
    Neoplasma; 2013; 60(4):425-31. PubMed ID: 23581415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance.
    Kuo CH; Lin SM; Lee KY; Chung FT; Hsieh MH; Fang YF; Yu CT; Kuo HP
    Clin Lung Cancer; 2010 Jan; 11(1):51-6. PubMed ID: 20085868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
    Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ
    J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR mutations as a predictive marker of cytotoxic chemotherapy.
    Park JH; Lee SH; Keam B; Kim TM; Kim DW; Yang SC; Kim YW; Heo DS
    Lung Cancer; 2012 Aug; 77(2):433-7. PubMed ID: 22521649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
    Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
    Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
    Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
    Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer.
    Zhuo ML; Wu MN; Zhao J; Song SW; Bai H; Wang SH; Yang L; An TT; Wang X; Duan JC; Wang YY; Guo QZ; Liu XY; Liu NH; Wang J
    Chin Med J (Engl); 2011 Nov; 124(21):3510-4. PubMed ID: 22340169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
    Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
    Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer.
    Lee HY; Ahn HK; Jeong JY; Kwon MJ; Han JH; Sun JM; Ahn JS; Park K; Choi YL; Ahn MJ
    Lung Cancer; 2013 Jan; 79(1):40-5. PubMed ID: 23103072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
    Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic Analysis of Patients with Advanced Non-small Cell Lung Cancer 
in Different Genotypes].
    Liu P; Wu Y; Zhou L; Qin N; Zhang Q; Zhang H; Li X; Zhang X; Lv J; Yang X; Wang J; Zhang S
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):741-750. PubMed ID: 29167003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.
    Chiari R; Metro G; Iacono D; Bellezza G; Rebonato A; Dubini A; Sperduti I; Bennati C; Paglialunga L; Burgio MA; Baglivo S; Giusti R; Minotti V; Delmonte A; Crinò L
    Lung Cancer; 2015 Nov; 90(2):255-60. PubMed ID: 26395848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.
    Koh Y; Kim DW; Kim TM; Lee SH; Jeon YK; Chung DH; Kim YW; Heo DS; Kim WH; Bang YJ
    J Thorac Oncol; 2011 May; 6(5):905-12. PubMed ID: 21358343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.
    Wang S; An T; Wang J; Zhao J; Wang Z; Zhuo M; Bai H; Yang L; Zhang Y; Wang X; Duan J; Wang Y; Guo Q; Wu M
    Clin Cancer Res; 2010 Feb; 16(4):1324-30. PubMed ID: 20145159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy.
    Morodomi Y; Takenoyama M; Inamasu E; Toyozawa R; Kojo M; Toyokawa G; Shiraishi Y; Takenaka T; Hirai F; Yamaguchi M; Taguchi K; Seto T; Sugio K; Ichinose Y
    Anticancer Res; 2014 Jul; 34(7):3825-30. PubMed ID: 24982409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.